SkinHealth Systems Inc. SKIN R2K
Company Overview
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
Why Investors Should Care
Revenue has grown at a 10.3% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $300.79M (-10.0% YoY); net profit $-9.52M.
- Trailing 12 Months Year-on-year growth — revenue -7.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.35% |
| 1 Year: | -7.80% |
Stock Price Performance
| 1 Year: | +357.14% |
| 6 Months: | +1,178.50% |
| 3 Months: | +1,354.55% |
| 1 Month: | +1,548.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 65.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SKIN SkinHealth Systems Inc. R2K | 10.88 | -47.30 | $1.42B | 0.00% | -6.64% | -43.89% | 10.35% | - |
| 2 | WMT Walmart Inc. SPXR3K | 119.89 | 43.44 | $951.18B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 1,003.32 | 48.38 | $444.60B | 0.62% | 25.96% | 28.40% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 92.71 | 27.84 | $398.89B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 161.02 | 24.32 | $374.28B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 199.47 | 27.40 | $310.90B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 135.77 | 17.79 | $185.46B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 84.26 | 18.16 | $147.21B | 1.80% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | MO Altria Group, Inc. SPXR3K | 74.31 | 15.64 | $124.08B | 6.37% | 38.27% | - | 1.24% | -1.89% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 14.12M | 34.56M | 47.54M | 66.51M | 68.15M | 75.42M | 103.54M | 88.79M | 86.28M | 117.48M | 97.41M | 81.40M | 90.59M | 78.80M | 69.58M | 78.19M | 70.66M | 64.91M | 72.11M |
| Gross Profit | - | 4.28M | 20.96M | 31.74M | 47.25M | 46.08M | 50.88M | 70.04M | 61.36M | 54.10M | 67.88M | -12.55M | 48.36M | 40.94M | 40.65M | 48.58M | 49.11M | 45.63M | 44.44M | 49.34M |
| Operating Income | - | -7.92M | 2.79M | 2.38M | -26.35M | -5.46M | -14.01M | -5.03M | -4.35M | -17.31M | -13.15M | -82.10M | -16.99M | -22.11M | -21.52M | -12.02M | -2.70M | -6.24M | -1.80M | 3.57M |
| Net Income | -9.07M | -10.40M | -2.21M | -3.27M | -139.38M | -215.15M | 31.45M | 6.32M | -81.00K | -20.26M | 3.36M | -73.82M | -679.00K | 202.00K | -18.29M | -10.10M | 19.71M | -11.03M | -6.63M | -2.67M |
| Diluted EPS | - | -0.30 | -0.06 | -0.09 | -1.52 | -1.63 | -0.13 | -0.06 | -0.03 | -0.15 | 0.03 | -0.56 | -0.10 | -0.10 | -0.15 | -0.08 | 0.03 | -0.09 | -0.05 | -0.02 |
| R&D Expense | - | 597.00K | 577.00K | 1.45M | 2.99M | 1.88M | 2.23M | 2.60M | 2.17M | 2.34M | 2.88M | 1.84M | 2.81M | 1.16M | 1.11M | 998.00K | 1.25M | 1.70M | 1.10M | 1.41M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 166.62M | 119.09M | 260.09M | 365.88M | 397.99M | 334.29M | 300.79M |
| Gross Profit | 106.51M | 67.20M | 178.54M | 248.78M | 155.11M | 182.30M | 196.36M |
| Operating Income | 13.46M | -17.18M | -39.93M | -25.84M | -130.92M | -67.77M | -20.80M |
| Net Income | -1.64M | -29.18M | -378.76M | 44.22M | -100.12M | -29.10M | -9.52M |
| Diluted EPS | -0.05 | -0.85 | -3.71 | -0.23 | -0.76 | -0.36 | -0.16 |
| R&D Expense | 4.61M | 3.41M | 8.20M | 8.44M | 10.10M | 6.30M | 5.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 222.84M | 1.22B | 1.00B | 929.11M | 685.68M | 499.80M |
| Total Equity | 294.00K | -1.21M | -30.57M | 298.03M | 167.05M | 59.39M | 51.80M | 61.06M |
| Cash & Equivalents | - | - | 9.49M | 901.89M | 568.20M | 523.02M | - | - |
| Total Liabilities | - | - | 252.79M | 916.51M | 836.03M | 869.72M | 633.88M | 438.75M |
| Current Liabilities | - | - | 30.93M | 76.44M | 71.71M | 115.01M | 68.15M | 186.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.73M | -12.44M | -28.36M | -106.60M | 21.75M | 16.13M | 37.48M |
| Investing Cash Flow | -12.48M | -3.82M | -37.73M | -18.87M | -31.51M | -6.79M | -5.16M |
| Financing Cash Flow | 14.58M | 18.27M | 959.03M | -205.24M | -37.45M | -158.34M | -174.93M |
| Capital Expenditure | -8.77M | -3.50M | -11.20M | -10.85M | -3.83M | -756.00K | -303.00K |
| Free Cash Flow | -7.05M | -15.94M | -39.56M | -117.45M | 17.93M | 15.38M | 37.18M |
| Share Buybacks | 0 | 154.00K | 0 | 160.00M | 30.16M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 63.9% | 56.4% | 68.6% | 68.0% | 39.0% | 54.5% | 65.3% |
| Operating Margin % | 8.1% | -14.4% | -15.4% | -7.1% | -32.9% | -20.3% | -6.9% |
| Net Margin % | -1.0% | -24.5% | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% |
| ROE % | 135.6% | 95.4% | -127.1% | 26.5% | -168.6% | -56.2% | -15.6% |
| ROCE % | - | -9.0% | -3.5% | -2.8% | -16.1% | -11.0% | -6.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Capricorn Fund Managers Ltd | 17.12% | 22.28M | $12.25M |
| 2 | FMR, LLC | 7.84% | 10.20M | $5.61M |
| 3 | Blackrock Inc. | 6.54% | 8.52M | $4.68M |
| 4 | Millennium Management Llc | 5.79% | 7.54M | $4.15M |
| 5 | Vanguard Capital Management LLC | 2.69% | 3.50M | $1.92M |
| 6 | Woodline Partners LP | 1.79% | 2.33M | $1.28M |
| 7 | Silver Point Capital L.p. | 1.22% | 1.59M | $875.62K |
| 8 | Shaw D.E. & Co., Inc. | 1.10% | 1.43M | $787.77K |
| 9 | Geode Capital Management, LLC | 0.74% | 960.37K | $528.21K |
| 10 | UBS Group AG | 0.64% | 839.38K | $461.66K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SKIN
SkinHealth Systems Inc. (SKIN) Soars 9.0%: Is Further Upside Left in the Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNdTdpUkpERmxQV1NaTzBGVkFhQ1V1OGg5aFhkOE5ieVhudkMzanR2aXM3WEpBYW5WLW9KYm0yU2k2bmZiSDU1Wmx2dXFUMEhBVDRSaE81UWd6TWxVU3pMMVl3cmEtbUM0ZmhGOGMyWm9TQzhkd0VjRG9zRU5DbUpTaUdRRDF1VUdETFVGLW…
SkinHealth Systems' results call is set for 4:30 p.m. Eastern time Nov. 5. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPSk9tZ1AwN01zUWk0Z2V5SldvYVoxaE9lczJtVTdjVUlMZ3Q1TzJRcC1YZjU3eGdrMWE2TnZJa0RwSmNuRlZXVWZqa2UwV2hQVi1rcXRKWTd3OU1Fb25SSjVsWEpVZ0lKakNnNGpIMS1WMWVvcmxoZVh6azhtRW4wbDBseFdKaTdMYVpuWi…
Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential - Investing.com
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPYjc5OUF4Z1RSaUNsb3pnQzlvRWt0R01zMlFjN3ZVRm96ZHIzSGdPUzUyUkx5TWlsNUJ6RWNoQkR1WkpQUE5uTUM0Ni1SMzFMMExEVHQ4RTI0aGVGSWU0OXVMNHM3b18ydzhmMGVSMEVqWV92RDFsRnVyTUpsa2FoV0R2aE4wU1BKTm5Fb2…
SKIN: Stockholders voted on a reverse stock split and adjournment, with results to be filed in Form 8-K - TradingView
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxNT2Nob1RfT2ZKY2FlTm5sNmFXT0RSVTh2S09Hb2xzTlZQbmhKWVpKTXBHNFNaYlpZSDVmQ3AzNFVBVVZTT1lmeUdiVE0zLVJGbWtkVTA1Sjc4SFQwdHk3dGdFSVk1SVZRYURfWkZEV3ZGX0VaWmIwOWJjUVAxU2ZrMWJtdkliRFMxNlZfWD…
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQTGFDakUtMkg4bWZSZ2VhYWhLX2lqWTlYeThwTGN2akViaUktWVVnUk9PaFdPX3JaX2o2U1Fjcy1uc2tlYklYcVlvcC0wODA1NG1KT1dCR0gxdlpVNW9FZEd4QmpmUktub3ZPQWc1UVV1NmNiQU5tNTlCaUpxWjVCRFBOY2hVdzNuY2ZFcV…
Nu Skin: The Turnaround Is Behind Before It's Started (NYSE:NUS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPXzhUWDRKOG94R2F4Q0d3VkdIRGQ1cEpqMDQ2RnZTdFlHRndvVDBxcG1ZMEhwWTFxSXVuNWkwT3VXc0o1T2RuLW1kUWVSU0JxQ19LZlg3Q2h2TTh5cUNBUkg4NVBESjBNSmJvWE5EeGZWRkxpcU5DU2w4YmdQbWxsU3V6SDA3VFctZmk3SE…
SKIN — Frequently Asked Questions
What is the current share price of SkinHealth Systems Inc. (SKIN)?
As of 2026-10-23 16:27 PDT, SkinHealth Systems Inc. (SKIN) trades at $10.88 on NasdaqCM. Its 52-week range is $0.55 to $31.10.
What is the market capitalisation of SKIN?
SkinHealth Systems Inc. (SKIN) has a market capitalisation of $1.42B on NasdaqCM.
What is the P/E ratio of SKIN?
SKIN trades at a trailing price-to-earnings (P/E) ratio of -47.30. The industry average P/E is 19.62. Its price-to-book (P/B) ratio is 1.58.
What is the return on equity (ROE) of SKIN?
SKIN has a return on equity (ROE) of -43.89%. Its return on capital employed (ROCE) is -6.64%.
Is SKIN a good stock to buy?
This page provides a data-driven analysis of SkinHealth Systems Inc. (SKIN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.